what-makes-hub-programs-successful- 
Drug Discovery World
NOVEMBER 24, 2022
DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies. . So, what can European countries do to encourage growth in drug discovery, attract investment and ensure long-term stability? What will improve Europe’s attractiveness for life sciences?
pharmaphorum
DECEMBER 18, 2022
Patient access solutions, including hubs and specialty pharmacies, play a vital role in getting patients started on therapy. However, the cumbersome hub workflow overshadows the purported gains in productivity. On top of that, traditional solutions provide delayed program data. What does this mean?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 28, 2022
The sooner a human-centred perspective is applied to the development of either a drug or device product, the more likely the product will be adopted and used because it’s been designed around what the end consumer wants and needs. determine what will help to create a compelling payer value story.
pharmaphorum
DECEMBER 20, 2022
In addition, the data revolution has raised concerns about privacy and maintaining patient trust, with many countries tightening regulations around what data can be collected and shared. Bring as many stakeholders to the table as possible. Sometimes policy solutions are the best starting point.
Creogenic Pharma
MARCH 8, 2021
‘Amazing Heritage Grand Experience’ is what we get from this nation. There is a number of pharma providers and medical distributors are associated with all our pharma franchise programs. Now it’s your turn to combine the best pharma company and get a successful start in the pharmaceutical sector by being our partner.
Drug Discovery World
APRIL 25, 2023
Small and medium sized enterprises (SMEs) that are investing over 40% of their total operating costs in R&D and not yet making a profit will receive a cash payment of 27p for each £1 they have invested in R&D. million in follow-up funding through BII’s Venture House program.
XTalks
APRIL 24, 2023
Dr. Eagleton recently spoke on a webinar with his colleagues from Medpace about lessons learned from successful approaches from rare disease and gene therapy product approvals. Bear in mind, particularly for Phase III pivotal studies, that what you study is what you’re getting on your label,” says Dr. Tangelder.
Expert insights. Personalized for you.
98 
Let's personalize your content